The top 10 hit parade of biopharma licensing deals for 2014-2017
The Merck KGaA logo stands illuminated at dusk outside the pharmaceutical company’s headquarters in Darmstadt, Germany, on November 3, 2016 Bloomberg
Biobucks remain the currency of choice in dealmaking, but it’s the hard upfront cash that tells us what kind of drugs are valued the highest. Not surprisingly, that covers three currently marketed drugs and seven experimental therapies for a total of $7.1 billion in down payments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.